ASC - Autism Study

Autism Spectrum Disorder Clinical Trial

Official title:

Effect of Adipose Tissue Derived Mesenchymal Stromal Cells on Autism and Leaky Gut Syndrome. A Phase I Pilot Study.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05602116
• Other study ID #: ASC II
• Status: Recruiting
• Phase: Phase 1
• Start date: June 9, 2023
• Est. completion date: February 1, 2026

Study information

• Verified date: June 2023
• Source: Cell2Cure ApS
• Contact: Jens Kastrup
• Phone: +45 21202994
• Email: jk[@]cell2cure.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The ASC - Autism Pilot Study is a single center randomized open dose titrating phase I clinical intervention pilot trial with the aim of investigating safety and treatment effect of an allogeneic adipose tissue derived mesenchymal stromal cell product (C2C_ASC) in children with autism spectrum disorder (ASD) and gastrointestinal symptoms.

Description:

The ASC - Autism Pilot Study will be performed at the Child and Adolescent Psychiatry, Aalborg University Hospital, Denmark. 10 children aged 6-14 years with ASD and gastrointestinal symptoms will be enrolled through the Child and Adolescent Psychiatry, Psychiatry Clinic South, Aalborg University Hospital, Denmark. The participants will randomly be divied into two treatment groups: 1. participant 1-5 will be treated with 1 x 1000000 C2C_ASCs/kg body weight 2. participant 6-10 will be treated with 2 x 1000000 C2C_ASCs/kg body weight C2C_ASC treatment: The C2C_ASCs product will be diluted in 50 ml isotonic saline and infused in an arm vein within 15 min. In both groups there will for each participant be a week observation for SAE's related to the cell treatment before the next participant will be treated, if no SAE's have been detected. The investigators hypothesize that the connection between gastrointestinal symptoms/leaky gut syndrome, increase local gastrointestinal and systemic elevated immunological and inflammatory activity, bacterial toxins in the blood and symptoms of ASD in children with symptoms of leaky gut syndrome can be reduced or normalized by modulating the immunological activity and inflammation by treatment with mesenchymal stromal cells.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: February 1, 2026
• Est. primary completion date: February 1, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years to 14 Years

Eligibility

Inclusion Criteria:

• Diagnosis of autism spectrum disorder.
• Ongoing gastrointestinal symptoms or previous gastrointestinal symptoms which disappeared or were reduced after dietary changes.
• Age 6 to 14 years.

Exclusion Criteria:

• Known genetic syndrome or pathogenic mutation or copy number variation associated with autism spectrum disorder.
• Known CNS-infection (now or previously) and/or HIV positivity.
• Primary immunodeficiency disorder or autoimmune cytopenia.
• Current treatment with cytotoxic drugs or systemic administered glucocorticoids and/or immunosuppressive therapy or other antiinflammatory medication (except nonsteroidal anti-inflammatory drugs).
• Epilepsy or known seizure disorder (now or previously).

Related Conditions & MeSH terms

• Autism Spectrum Disorder
• Autistic Disorder
• Gastrointestinal Dysfunction
• Inflammatory Bowel Diseases
• Leaky Gut Syndrome
• Mesenchymal Stromal Cells
• Syndrome

Intervention

Drug:
• Adipose tissue derived mesenchymal stromal/stem cells (Cell2Cure®)
The Investigational Product is a C2C_ASC cell product (Cell2Cure®, Cell2Cure Aps, Denmark). C2C_ASC is an advanced therapy investigational medicinal product (ATIMP) manufactured from abdominal adipose tissue derived mesenchymal stromal cells (ASC) from healthy donors. C2C_ASC is aseptically procured and manufactured according to tissue law and GMP by Cell2Cure ApS or Cardiology Stem Cell Center, Rigshospitalet, Copenhagen, Denmark, using manual isolation of cells from abdominal fat tissue, xeno-free cell expansion in automated closed bioreactor systems and cryopreservation of the final product. The active substance is the in vitro expanded ASCs. The final product, C2C_ASC, is provided as a cryopreserved suspension of 50 million ASCs per ml with a total volume of 1,3 ml per vial. The excipient is CryoStor10 (Biolife Solutions), holding 10% DMSO.

Locations

Country	Name	City	State
Denmark	Department of Child and Adolescent Psychiatry, Psychiatry Clinic South, Aalborg University Hospital, Denmark	Aalborg

Sponsors (1)

Lead Sponsor	Collaborator
Cell2Cure ApS

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety of C2C_ASC (Adverse Events)	Safety of C2C_ASC within the 12 weeks follow-up period: Adverse event (AE), serious adverse event (SAE), suspected unexpected serious adverse reaction (SUSAR) and development safety update report (DSUR).	12 weeks
Secondary	Changes in autism spectrum disorder	Difference from baseline to follow-up within the group treated with C2C_ASC: Changes in autism spectrum disorder score test (questionnaire).; [Raw scores converting to standard scores and then generates five major domain composite scores: communication, daily living skills, socialization, adaptive behavior composite and motor. For these domains a standard score of 100 is the mean with a standard deviation of 15. This means that a score of 100 is similar to the typical population of the same age. Scores in the range of 86 and above are considered adequate. Scores in the range of 85 and below indicates a significant skill deficit when comparing with the typical population of the same age.; High scores: standard scores of 130-140 Moderately high scores: standard scores of 115-129 Adequate scores: standard scores of 86-114 Moderately low scores: standard scores of 71-85 Low scores: standard scores of 20-70]	12 weeks
Secondary	Changes in gastrointestinal symptoms	Difference from baseline to follow-up within the group treated with C2C_ASC: Changes in The Infant Gastrointestinal Symptom Questionnaire (questionnaire).; [A 0-100 scale where higher scores indicate better irritable bowel syndrome specific quality of life.]	12 weeks